Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioAtla (BCAB) Research & Development (2020 - 2025)

BioAtla's Research & Development history spans 6 years, with the latest figure at $8.0 million for Q4 2025.

  • For Q4 2025, Research & Development fell 31.37% year-over-year to $8.0 million; the TTM value through Dec 2025 reached $43.6 million, down 30.94%, while the annual FY2025 figure was $43.6 million, 30.94% down from the prior year.
  • Research & Development reached $8.0 million in Q4 2025 per BCAB's latest filing, down from $9.5 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $31.0 million in Q2 2023 to a low of $8.0 million in Q4 2025.
  • Average Research & Development over 5 years is $17.4 million, with a median of $16.5 million recorded in 2021.
  • Peak YoY movement for Research & Development: skyrocketed 527.51% in 2021, then tumbled 48.62% in 2024.
  • A 5-year view of Research & Development shows it stood at $16.4 million in 2021, then soared by 32.99% to $21.9 million in 2022, then grew by 3.66% to $22.7 million in 2023, then plummeted by 48.62% to $11.6 million in 2024, then crashed by 31.37% to $8.0 million in 2025.
  • Per Business Quant, the three most recent readings for BCAB's Research & Development are $8.0 million (Q4 2025), $9.5 million (Q3 2025), and $13.7 million (Q2 2025).